View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 4, 2011

Pfizer Smoking Cessation Drug Linked to Heart Attacks

Pfizer's stop-smoking drug Chantix (varenicline) has been linked to cardiovascular problems such as heart attacks, according to a new report. Scientists in the US and UK wrote in an article published in the Canadian Medical Association Journal that said the drug was associated

By cms admin

Pfizer’s stop-smoking drug Chantix (varenicline) has been linked to cardiovascular problems such as heart attacks, according to a new report.

Scientists in the US and UK wrote in an article published in the Canadian Medical Association Journal that said the drug was associated with a 72% increased risk of serious adverse cardiovascular events compared to a placebo.

It also said that there were too few deaths during clinical trials “to allow meaningful comparisons of mortality”.

The researchers analysed data from 14 double-blind randomised controlled trials involving 8,216 participants. The trials ranged in duration from seven to 52 weeks.

Last month, the US Food and Drug Administration (FDA) urged Pfizer to add a warning label to the medication about its potential to increase the risk of heart attack in people who have already had one.

France removed Chantix from its list of state-approved drugs following the announcement from the FDA.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology